Hyperjaponol H, a New Bioactive Filicinic Acid-Based Meroterpenoid from Hypericum Japonicum Thunb. Ex Murray

Total Page:16

File Type:pdf, Size:1020Kb

Hyperjaponol H, a New Bioactive Filicinic Acid-Based Meroterpenoid from Hypericum Japonicum Thunb. Ex Murray Hyperjaponol H, A New Bioactive Filicinic Acid-based Meroterpenoid from Hypericum japonicum Thunb. ex Murray Rongrong Wu 1,†, Zijun Le 2,†, Zhenzhen Wang 3, Shuying Tian 1, Yongbo Xue 3, Yong Chen 1, Linzhen Hu 1, * and Yonghui Zhang 3 1 National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, Hubei Key Laboratory of Biotechnology of Chinese Traditional Medicine, School of Life Science, Hubei University, Wuhan 430062, Hubei Province, P. R. China; E-mails: [email protected] (R. R. W.); [email protected] (S. Y. T.); [email protected] (Y. C.) 2 Wuhan Rayson School, Wuhan 430040, Hubei Province, P. R. China; E-mail: [email protected] (Z. J. L.) 3 Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology; Wuhan 430030, Hubei, China; E-mails : [email protected] (Z. Z. W.); [email protected] (Y. B. X.); [email protected] (Y. H. Z.) † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-mail: [email protected] (L. Z. H.); Tel.: +86-27-88668023 (L. Z. H.) Content Figure S1. HRESIMS spectrum of hyperjaponol H (1) ..................................................................... 1 1 Figure S2. H NMR spectrum of hyperjaponol H (1, in CDCl3) ....................................................... 2 13 Figure S3. C NMR and DEPT135 spectra of hyperjaponol H (1, in CDCl3) .................................. 3 Figure S4. HSQC spectrum of hyperjaponol H (1, in CDCl3) ........................................................... 4 Figure S5. HMBC spectrum of hyperjaponol H (1, in CDCl3) .......................................................... 5 1 1 Figure S6. H– H COSY spectrum of hyperjaponol H (1, in CDCl3) ................................................ 6 Figure S7. NOESY spectrum of hyperjaponol H (1, in CDCl3) ........................................................ 7 Figure S8. UV spectrum of hyperjaponol H (1, in methanol) ........................................................... 8 Figure S9. IR spectrum of hyperjaponol H (1, KBr disc) ................................................................ 9 x10 4 +ESI Scan (0.106 min) Frag=70.0V 20180308-WRR.P.1.d 459.3119 2.4 2.2 2 1.8 1.6 1.4 1.2 1 0.8 460.3157 0.6 0.4 0.2 0 458.5 459 459.5 460 460.5 461 461.5 462 462.5 463 463.5 464 Counts vs. Mass-to-Charge (m/z) Figure S1. HRESIMS spectrum of hyperjaponol H (1) 1 1 Figure S2. H NMR spectrum of hyperjaponol H (1, in CDCl3) 2 13 Figure S3. C NMR and DEPT135 spectra of hyperjaponol H (1, in CDCl3) 3 Figure S4. HSQC spectrum of hyperjaponol H (1, in CDCl3) 4 Figure S5. HMBC spectrum of hyperjaponol H (1, in CDCl3) 5 1 1 Figure S6. H– H COSY spectrum of hyperjaponol H (1, in CDCl3) 6 Figure S7. NOESY spectrum of hyperjaponol H (1, in CDCl3) 7 Figure S8. UV spectrum of hyperjaponol H (1, in methanol) 8 E:\20171130\20171130HULINZ\1.0 Transmittance [%] 4000 91.5 92.0 92.5 93.0 93.5 94.0 94.5 95.0 3921.83 3875.63 3826.53 3757.82 3720.07 3673.41 3500 Figure S9. Figure 3455.00 3111.42 3000 IR spectrum of hyperjaponol H ( 2966.81 2932.80 2874.83 2500 2528.70 Wavenumber cm-1 Wavenumber 2381.44 9 2307.27 2224.30 2000 1919.37 1720.64 1 1654.55 , KBr disc) , KBrdisc) 1612.99 1500 1523.39 1464.58 1378.07 1313.52 1259.33 1189.42 1140.69 1000 1063.58 989.16 938.55 14:19:02 2017-11-30 881.82 821.45 752.01 676.82 619.55 500 579.85 501.85 457.07 .
Recommended publications
  • Vaccines Currently in Development
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES Begin Phase 1 trials in late TAK-888, antibodies from PhRMA spring. To patients between 1 recovered COVID-19 N/A Takeda Pre-clinical Wall Street Journal December 2020 and December patients Pink Sheet 2021 Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Antibodies from recovered Korea Herald 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 COVID-19 patients UPI Antibodies from recovered BioSpace 4 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 5 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech Antibodies from recovered Lilly/Ab-Cellera (NIH Vaccines 6 N/A Pre-clinical Start Phase 1 in late July 2020 Endpoints News COVID-19 patients Research Center) * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources. It is not an endorsement Copyright 2020 Updated April 2, 2020, at 2:30 p.m.
    [Show full text]
  • Current Situation and Development of University Libraries' Self-Built
    Advances in Social Science, Education and Humanities Research, volume 516 Proceedings of the 2020 3rd International Seminar on Education Research and Social Science (ISERSS 2020) Current Situation and Development of University Libraries’ Self-Built Resources in the Big Data Environment—A Case Study of Self-Built Database of Public University Libraries in Hubei Province Zhengyu Sha1 1Library of Wuhan University of Technology, Wuhan, Hubei 430070, China *Corresponding author. Email:[email protected] ABSTRACT The self-built resources of university libraries are an important part of the digital resource system of libraries. It is a long-term and necessary work to study sustainable development. This work investigated the self-built resources of 36 public undergraduate colleges and universities in Hubei province by means of website visits and network interviews, finding that there are some problems in current construction, such as outdated theme, backward technology and low utilization rate. It put forward transformation strategies such as introducing new artificial intelligence technology, reorganizing library big data, innovating library services, positioning the development direction of self-built resources, and collaboratively constructing university big data, so as to provide reference for the transformation and construction of self-built resources to adapt to intelligent technology. Keywords: University library, Database, Self-built resources, Big data, Artificial intelligence database research literature in colleges and universities, and finds that the research peak is between 2008 and 2014, 1. INTRODUCTION and then decreases year by year [3]. The research is basically consistent with the actual construction of a self- In the 1990s, the development of Internet technology has built database.
    [Show full text]
  • Journal of Clinical Review & Case Reports
    ISSN: 2573-9565 Review Article Journal of Clinical Review & Case Reports A Mathematical Model of Clinical Diagnosis and Treatment on the Method of Fuzzy Duster Analysis Bin Zhao1*, Xia Jiang2, Kuiyun Huang1, Jinming Cao3 and Jingfeng Tang4 1School of Science, Hubei University of Technology, Wuhan, Hubei, China * 2Hospital, Hubei University of Technology, Wuhan, Hubei, China Corresponding author Dr. Bin Zhao, School of Science, Hubei University of Technology, Wuhan, 3School of Information and Mathematics, Yangtze University, Hubei, China, Tel/Fax: +86 130 2851 7572; E-mail: zhaobin835@nwsuaf. Jingzhou, Hubei, China edu.cn 4National “111” Center for Cellular Regulation and Molecular Submitted: 21 Jan 2019; Accepted: 28 Jan 2019; Published: 11 Feb 2019 Pharmaceutics, Hubei University of Technology, Wuhan, Hubei, China Abstract In the process of this paper, all the factors related to cervical scoliosis can be grouped into 6 kinds of factors (5 levels), and all the possibilities of the cervical scoliosis can be divided into five classes. A fuzzy logic study was performed on 318 patients who had undergone cervical scoliosis with our hospital from August 2013 to August 2018. And the clinical diagnosis and treatment on the method of fuzzy duster are analyzed with the mathematical model be established. Then, we study a new differentiated diagnosis method of cervical torticollis (scoliosis) by an Asian wild horse with fuzzy mathematics, and successfully treated after cervical nerve plexus block. Keywords: Clinical Diagnosis; Treatment; Cervical Torticollis; paralysis subsequent to cervical spinal nerve damage and nutritional Scoliosis; Fuzzy Cluster Analysis dystrophic myo-degeneration [2]. This clinical report describes a technique for correction of an acquired cervical torticollis in a horse.
    [Show full text]
  • A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Breast Cancer After Adjuvant Trastuzumab- Based Treatment F
    www.nature.com/scientificreports OPEN Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab- based treatment F. Du, P. Yuan, Z. T. Zhao, Z. Yang, T. Wang, J. D. Zhao, Y. Luo, F. Ma, J. Y. Wang, Y. Fan, R. G. Cai, P. Zhang, Q. Li, Y. M. Song & B. H. Xu Scientific Reports 6:33825; doi: 10.1038/srep33825; published online 21 September 2016; updated on 14 October 2016 The Acknowledgements section in the PDF version of this Article is incorrect. “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C0466), and funded by the Ministry of Health & Welfare, Republic of Korea (HI14C3344)”. should read: “The following institutions participated in this study: Fudan University Shanghai Cancer Center; Zhejiang Cancer Hospital; Guangdong General Hospital; Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology; Nanfang Hospital, Southern Medical University; Sun Yat-Sen University Cancer Hospital; West China Hospital, Sichuan University; Harbin Medical University Cancer Hospital; Henan Cancer Hospital, Zhengzhou University; Peking Union Medical College Hospital. This work was supported by Beijing Hope Run Special Fund (LC2013L09) and Capital Clinical Feature Applied Research Fund (Z141107002514010).
    [Show full text]
  • Research on Sustainable Land Use Based on Production–Living–Ecological Function: a Case Study of Hubei Province, China
    sustainability Article Research on Sustainable Land Use Based on Production–Living–Ecological Function: A Case Study of Hubei Province, China Chao Wei 1, Qiaowen Lin 2, Li Yu 3,* , Hongwei Zhang 3 , Sheng Ye 3 and Di Zhang 3 1 School of Public Administration, Hubei University, Wuhan 430062, China; [email protected] 2 School of Management and Economics, China University of Geosciences, Wuhan 430074, China; [email protected] 3 School of Public Administration, China University of Geosciences, Wuhan 430074, China; [email protected] (H.Z.); [email protected] (S.Y.); [email protected] (D.Z.) * Correspondence: [email protected]; Tel.: +86-185-7163-2717 Abstract: After decades of rapid development, there exists insufficient and contradictory land use in the world, and social, economic and ecological sustainable development is facing severe challenges. Balanced land use functions (LUFs) can promote sustainable land use and reduces land pressures from limited land resources. In this study, we propose a new conceptual index system using the entropy weight method, regional center of gravity theory, coupling coordination degree model and obstacle factor identification model for LUFs assessment and spatial-temporal analysis. This framework was applied to 17 cities in central China’s Hubei Province using 39 indicators in terms of production–living–ecology analysis during 1996–2016. The result shows that (1) LUFs showed an overall upward trend during the study period, while the way of promotion varied with different dimensions. Production function (PF) experienced a continuous enhancement during the study period. Living function (LF) was similar in this aspect, but showed a faster rising tendency.
    [Show full text]
  • Formation Mechanism for Upland Low-Relief Surface Landscapes in the Three Gorges Region, China
    remote sensing Article Formation Mechanism for Upland Low-Relief Surface Landscapes in the Three Gorges Region, China Lingyun Lv 1,2, Lunche Wang 1,2,* , Chang’an Li 1,2, Hui Li 1,2 , Xinsheng Wang 3 and Shaoqiang Wang 1,2,4 1 Key Laboratory of Regional Ecology and Environmental Change, School of Geography and Information Engineering, China University of Geosciences, Wuhan 430074, China; [email protected] (L.L.); [email protected] (C.L.); [email protected] (H.L.); [email protected] (S.W.) 2 Hubei Key Laboratory of Critical Zone Evolution, School of Geography and Information Engineering, China University of Geosciences, Wuhan 430074, China 3 Hubei Key Laboratory of Regional Development and Environmental Response, Hubei University, Wuhan 430062, China; [email protected] 4 Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences, Beijing 100101, China * Correspondence: [email protected] Received: 9 November 2020; Accepted: 26 November 2020; Published: 27 November 2020 Abstract: Extensive areas with low-relief surfaces that are almost flat surfaces high in the mountain ranges constitute the dominant geomorphic feature of the Three Gorges area. However, their origin remains a matter of debate, and has been interpreted previously as the result of fluvial erosion after peneplain uplift. Here, a new formation mechanism for these low-relief surface landscapes has been proposed, based on the analyses of low-relief surface distribution, swath profiles, χ mapping, river capture landform characteristics, and a numerical analytical model. The results showed that the low-relief surfaces in the Three Gorges area could be divided into higher elevation and lower elevation surfaces, distributed mainly in the highlands between the Yangtze River and Qingjiang River.
    [Show full text]
  • Curriculum Vitae Huiyun Xiang, M.D
    Curriculum Vitae Huiyun Xiang, M.D., M.P.H., Ph.D. Professional Address Home Address Center for Injury Research and Policy 4506 Bradford Road The Research Institute at Nationwide Children’s Hospital Upper Arlington, OH 43220 700 Children’s Drive Phone: (614) 459-8248 Columbus, OH 43205 Phone: (614) 355-2768 Fax: (614) 722-2448 Email: [email protected] Academic Education 1999 Ph.D. College of Veterinary Medicine and Biomedical Sciences Colorado State University Major: Injury Epidemiology 1991 M.P.H. School of Public Health Tongji Medical College Major: Health Statistics 1988 M.D. Tongji Medical College Major: Preventive Medicine Special Training 2006-2007 Upper Arlington Leadership Program City of Upper Arlington, Columbus, Ohio 2001-2002 Advanced Public Health Leadership Fellow Regional Institute for Health & Environmental Leadership Denver University 2000 Colorado Advanced Supervisory Leadership Training Colorado State Department of Personnel and Administration 1999 Colorado Supervisory Leadership Training Colorado State Department of Personnel and Administration Professional Employment Huiyun Xiang, MD MPH PhD - 2 - 2009-Present Associate Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s Hospital Department of Pediatrics College of Medicine The Ohio State University 2003- 2008 Assistant Professor Associate Director of Professional Development Center for Injury Research and Policy The Research Institute at Nationwide Children’s
    [Show full text]
  • (TJDBPS01): Study Protocol for a Multicenter Randomized Controlled Trial
    Total laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy (TJDBPS01): study protocol for a multicenter randomized controlled trial. Hang Zhang1, Junfang Zhao1, Yechen Feng1, Rufu Chen2, Xuemin Chen3, Wei Cheng4, Dewei Li5, Jingdong Li6, Xiaobing Huang7, Heguang Huang13, Deyu Li14, Jing Li7, Jianhua Liu8, Jun Liu9, Yahui Liu10, Zhijian Tan11, Xinmin Yin4, Wenxing Zhao12, Yahong Yu1, Min Wang1✉, Renyi Qin1 ✉. Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China’s International Exchange and Promotion Association for Medicine and Healthcare. 1 Department of Biliary–Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. 2 Department of Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China. 3 Department of Pancreaticobiliary Surgery, The Third Affiliated Hospital of Soochow University, Jiangsu 213000, China. 4 Department of Hepatobiliary Surgery, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan 410000, China. 5 Department of Hepatobiliary Surgery, First Affiliated Hospital of Chongqing Medical University, Chongqing 404100, China. 6 Department of Pancreatico-Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Sichuan 637000, China. 7 Department of Pancreatico-Hepatobiliary Surgery, The Second Affiliated Hospital, Army Medical University, PLA, Chongqing 404100, China. 8 Department of Hepato–Pancreato–Biliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, China. 9 Department of Hepato–Pancreato–Biliary Surgery, Shandong Provincial Hospital, Shandong 250000, China. 10 Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, China. 11 Department of Hepatobiliary and Pancreatic Surgery, Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China.
    [Show full text]
  • A Collaborative Online AI Engine for CT-Based COVID-19 Diagnosis
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.10.20096073; this version posted May 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 A collaborative online AI engine for CT-based COVID-19 diagnosis 2 3 Yongchao Xu1,2#, Liya Ma1#, Fan Yang3#, Yanyan Chen4#, Ke Ma2, Jiehua Yang2, Xian Yang2, Yaobing 4 Chen 5, Chang Shu2, Ziwei Fan2, Jiefeng Gan2, Xinyu Zou2, Renhao Huang2, Changzheng Zhang6, 5 Xiaowu Liu6, Dandan Tu6, Chuou Xu1, Wenqing Zhang2, Dehua Yang7, Ming-Wei Wang7, Xi Wang8, 6 Xiaoliang Xie8, Hongxiang Leng9, Nagaraj Holalkere10, Neil J. Halin10, Ihab Roushdy Kamel11, Jia Wu12, 7 Xuehua Peng13, Xiang Wang14, Jianbo Shao13, Pattanasak Mongkolwat15, Jianjun Zhang16,17, Daniel L. 8 Rubin18, Guoping Wang 5, Chuangsheng Zheng3*, Zhen Li1*,Xiang Bai2*, Tian Xia2,5* 9 1Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and 10 Technology, Wuhan 430030, China. 11 2School of Electronic Information and Communications, Huazhong University of Science and Technology, Wuhan 12 430074, China. 13 3Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and 14 Technology, Wuhan 430022, China. 15 4Department of Information Management, Tongji Hospital, Huazhong University of Science and Technology, 16 Wuhan 430030, China. 17 5Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 18 Wuhan 430030, China. 19 6HUST-HW Joint Innovation Lab, Wuhan 430074, China.
    [Show full text]
  • Engineered Interferon Alpha Effectively Improves Clinical Outcomes of COVID-19 Patients
    Engineered interferon alpha effectively improves clinical outcomes of COVID-19 patients Chuan Li Department of Thoracic Surgery, West China Hospital, Sichuan University Fengming Luo Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chengwu Liu Department of Thoracic Surgery, West China Hospital, Sichuan University Nian Xiong Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Zhihua Xu Department of Critical Care Medicine, Mianyang Central Hospital Wei Zhang Department of Respiratory and Critical Care Medicine, First aliated hospital, the Second Military Medical University Ming Yang Department of Respiratory Medicine, The Public Health Clinical Center of Chengdu Ye Wang Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Dan Liu Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Chao Yu Department of Respiratory and Critical Care Medicine, Naval Hospital of Eastern Theater of PLA Jia Zeng Department of Aviation Disease, Naval medical center of PLA, the Second Military Medical University Li Zhang Department of Respiratory Disease, Wuhan Red Cross Hospital Duo Li Department of Respiratory Disease, The Aliated Hospital of Southwest Medical University Yanbin Liu Center of Infectious Diseases, West China Hospital, Sichuan University Mei Feng Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University Ruoyang Liu Page 1/21 Department
    [Show full text]
  • Northeast Ohio Medical University
    NORTHEAST OHIO MEDICAL UNIVERSITY DEPARTMENT OF ANATOMY & NEUROBIOLOGY Presents Synapses, muscular dystrophy and schizophrenia By Lin Mei, Ph.D. Chairman & Professor Department of Neurosciences School of Medicine Case Western Reserve University Director Cleveland Brain Health Initiative Thursday, January 10, 2019 4:00 p.m. F-118 For further information, please call (330) 325-6293 or (330) 325-6636 Page 1 of 37 Lin Mei Curriculum Vitae Department of Neurosciences School of Medicine Case Western Reserve University 10900 Euclid Ave. Cleveland, OH 44106-4975 Office Phone: 216-368-4928 Email: [email protected] Education: Diploma of Medicine, 1982, Jiangxi Medical College, Nanchang, China M.S. (Neuropharmacology), 1985, Institute of Pharmacology & Toxicology, Beijing, China. Advisor: Professor Jin-Chu Yan PhD (Pharmacology and Toxicology), 1989, University of Arizona, Tucson, Arizona. Advisors: Professors Henry I. Yamamura and William Roeske Appointments: 1981-1982, Intern, First Affiliated Hospital, Jiangxi Medical College, Nanchang, China 1989-1994, Postdoctoral Fellow/Research Associate, HHMI, Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, Maryland. Advisor: Professor Richard Huganir 1994-1999, Assistant Professor, Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 1999-2002, Assistant Professor, Neurobiology, Pathology, and Physical Medicine and Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama 2002-2004, Associate Professor, Neurobiology,
    [Show full text]
  • Abstract Submission/Modification Form
    Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study Yuqin Song, MD, PhD,1 Quanli Gao, MD,2 Huilai Zhang, PhD,3 Lei Fan, MD, PhD,4 Jianfeng Zhou, PhD,5 Dehui Zou, MD,6 Wei Li, MD,7 Haiyan Yang, PhD,8 Ting Liu, MD, PhD,9 Quanshun Wang, MD, PhD,10 Fangfang Lv, MD,11 Yu Yang, MD,12 Haiyi Guo, MD,13 Liudi Yang, MD,13 Rebecca Elstrom, 13 13 13 13 1 MD, Jane Huang, MD, William Novotny, MD, Vivian Wei, PhD, and Jun Zhu, MD, PhD 1Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China 2Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China 3Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, China 4Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China 5Department of Hematology, Tongji Hospital, Tongji Medical College, Wuhan, China 6State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China 7Department of Hematology, Cancer Center, The First Hospital of Jilin University, Changchun, China 8Department of Oncology, Zhejiang
    [Show full text]